The first generation of anticancer drug-loaded nanomachines are already in a Phase Ⅱ clinical trials. In this theme, a next generation of nanomachines will be developed to target and cure intractable cancers, such as brain tumors,metastatic cancers and cancer stem cells. Our goal is to reduce the mortality rate from cancer.

Participating institutions
Innovation Center of NanoMedicine(iCONM),
Kowa Company, Ltd., JSR Corporation,
NanoCarrier Co.,Ltd., Nitto Boseki Co.,Ltd.,
Nippon Kayaku Co.,Ltd., Japan Radioisotope Association,
National Cancer Center, The University of Tokyo

The brain is strongly protected by the blood-brain barrier (BBB) , a construct that primarily consists of brain capillary endothelial cells (BCECs) and astrocytes, through which it is difficult to deliver a biologically active substance.
An effective therapeutic approach has not been found although our aging society is suffering from a high prevalence of central nervous system (CNS) diseases. This research theme aims to develop an innovative therapeutic technology for CNS diseases, such as Alzheimer's disease, by creating a nanomachine that can deliver diverse biologically active substances to the brain.

Participating institutions
Innovation Center of NanoMedicine (iCONM) ,
Tokyo Medical and Dental University, Braizon Therapeutics Inc.,
The University of Tokyo

A nanomachine for delivering messenger RNA (mRNA) , which is next-generation "nucleic acid-based therapeutics," is currently in development. By delivering mRNA to the necessary place at the necessary time to produce proteins that can improve and/or restore the functions of motor and sensory cells, definitive treatment will be actualized against intractable diseases such as central nervous system disorders and age-related motor and sensory disorders.
Development of vaccines against viruses including COVID-19 using this technology are also being carried out.

Participating institutions
Innovation Center of NanoMedicine (iCONM) ,
NOF Corporation, Central Institute for Experimental Animals,
NanoCarrier Co.,Ltd., Tokyo Medical and Dental University,
The University of Tokyo

A quick cancer diagnostic device will be developed that separates, purifies and detects circulating microRNAs in the blood with high sensitivity. Noninvasive diagnostic devices will also be developed that determine the profiles of microRNAs and amino acids in urine and saliva. The research team will lead in creation of innovative diagnostic technology that will support future preventive medicine and home healthcare.

Participating institutions
Innovation Center of NanoMedicine(iCONM),
Tokyo Medical and Dental University, Tokyo Medical University,
The University of Tokyo

This theme aims to develop a pinpoint diagnostic and therapeutic technology that removes the diseased area while minimizing damage to the healthy tissue by combining a nanomachine that delivers imaging molecules or an agent that is activated by light, ultrasonic waves or neutron irradiation with medical equipment, such as MRI and allay-type ultrasound transducer.

Participating institutions
Innovation Center of NanoMedicine(iCONM),
SBI Pharmaceuticals Co.,Ltd., Toray Industries Inc.,
National Institutes for Quantum and Radiological Science and Technology,
Tokyo Institute of Technology, Tokyo Women's Medical University,
Tokyo University of Science, The University of Tokyo

With an aim to achieve smart healthcare society by "In-Body Hospitals", we will conduct several researches: Open innovation management, Regulatory science of nano-medicine, and Business model generation in the field of preventive medicine.

Participating institutions
Innovation Center of NanoMedicine(iCONM),
Shimadzu Corporation,
Nitto Denko Corporation,
Fujifilm Corporation, Medical Industry Innovation Institute(Mi3),
Tokyo Institute of Technology, The University of Tokyo